Researchers in the legacy organization of Baylor Scott & White Health are now working together to create more treatments options for patients. One area of exciting innovation has been in immunotherapy, where the body’s immune system is used to recognize disease like cancer and build antibodies to fight against it.
More than 2,000 active clinical studies are available right now to patients at Baylor Scott & White. Further, Baylor Research Institute announced in May 2015 that they would enter into a new agreement with Translational Genomics Research Institute, also known as TGen, to collaborate on precision medicine studies. This research will bring patients in Texas greater access to innovative therapies such as liquid biopsies, gene sequencing, and personalized vaccines. Read more on this collaboration.